{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T01:03:58Z","timestamp":1762995838604,"version":"3.45.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,12]]},"DOI":"10.7759\/cureus.96706","type":"journal-article","created":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T00:59:55Z","timestamp":1762995595000},"source":"Crossref","is-referenced-by-count":0,"title":["Multifocal Presentations of Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD): A Case Series From a District General Hospital in South East England"],"prefix":"10.7759","author":[{"given":"Mohamed Saifaldin Eltayieb","family":"Mohamed","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Doaa Mahmoud Akasha","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mok","family":"Tzehow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elin","family":"Gurung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Habeeb","family":"Jarral","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.885218","article-title":"Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): a review of clinical and MRI features, diagnosis, and management","volume":"13","author":"Sechi E","year":"2022","unstructured":"Sechi E, Cacciaguerra L, Chen JJ, et al.. Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): a review of clinical and MRI features, diagnosis, and management. Front Neurol. 2022, 13:885218. 10.3389\/fneur.2022.885218","journal-title":"Front Neurol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-018-0112-x","article-title":"Myelin oligodendrocyte glycoprotein antibodies in neurological disease","volume":"15","author":"Reindl M","year":"2019","unstructured":"Reindl M, Waters P. Myelin oligodendrocyte glycoprotein antibodies in neurological disease. Nat Rev Neurol. 2019, 15:89-102. 10.1038\/s41582-018-0112-x","journal-title":"Nat Rev Neurol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(21)00218-0","article-title":"Myelin-oligodendrocyte glycoprotein antibody-associated disease","volume":"20","author":"Marignier R","year":"2021","unstructured":"Marignier R, Hacohen Y, Cobo-Calvo A, et al.. Myelin-oligodendrocyte glycoprotein antibody-associated disease. Lancet Neurol. 2021, 20:762-72. 10.1016\/S1474-4422(21)00218-0","journal-title":"Lancet Neurol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-018-1144-2","article-title":"MOG encephalomyelitis: international recommendations on diagnosis and antibody testing","volume":"15","author":"Jarius S","year":"2018","unstructured":"Jarius S, Paul F, Aktas O, et al.. MOG encephalomyelitis: international recommendations on diagnosis and antibody testing. J Neuroinflammation. 2018, 15:134. 10.1186\/s12974-018-1144-2","journal-title":"J Neuroinflammation"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-014-0224-x","article-title":"Influenza-associated MOG antibody-positive longitudinally extensive transverse myelitis: a case report","volume":"14","author":"Amano H","year":"2014","unstructured":"Amano H, Miyamoto N, Shimura H, et al.. Influenza-associated MOG antibody-positive longitudinally extensive transverse myelitis: a case report. BMC Neurol. 2014, 14:224. 10.1186\/s12883-014-0224-x","journal-title":"BMC Neurol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1097\/WNO.0000000000001234","article-title":"Myelin oligodendrocyte glycoprotein antibody-associated optic neuritis-a review","volume":"41","author":"Kaushik M","year":"2021","unstructured":"Kaushik M, Burdon MA. Myelin oligodendrocyte glycoprotein antibody-associated optic neuritis-a review. J Neuroophthalmol. 2021, 41:e786-95. 10.1097\/WNO.0000000000001234","journal-title":"J Neuroophthalmol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.59938","article-title":"Extremely longitudinally extensive transverse myelitis in a patient with myelin oligodendrocyte glycoprotein antibody-associated disease","volume":"16","author":"Okubo S","year":"2024","unstructured":"Okubo S, Kakumoto T, Tsujita M, et al.. Extremely longitudinally extensive transverse myelitis in a patient with myelin oligodendrocyte glycoprotein antibody-associated disease. Cureus. 2024, 16:e59938. 10.7759\/cureus.59938","journal-title":"Cureus"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ensci.2022.100432","article-title":"MOG antibody associated disease (MOGAD) presenting with extensive brain stem encephalitis: a case report","volume":"29","author":"Olbert E","year":"2022","unstructured":"Olbert E, Brunner C, Alhani N, Na\u0161el C, Struhal W. MOG antibody associated disease (MOGAD) presenting with extensive brain stem encephalitis: a case report. eNeurologicalSci. 2022, 29:100432. 10.1016\/j.ensci.2022.100432","journal-title":"eNeurologicalSci"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-023-11738-7","article-title":"Optic neuritis and MOGAD","volume":"270","author":"Htet ZM","year":"2023","unstructured":"Htet ZM, Tallantyre E. Optic neuritis and MOGAD. J Neurol. 2023, 270:3278-9. 10.1007\/s00415-023-11738-7","journal-title":"J Neurol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200309","article-title":"A simple score (MOG-AR) to identify individuals at high risk of relapse after MOGAD attack","volume":"11","author":"Xu Y","year":"2024","unstructured":"Xu Y, Meng H, Fan M, et al.. A simple score (MOG-AR) to identify individuals at high risk of relapse after MOGAD attack. Neurol Neuroimmunol Neuroinflamm. 2024, 11:e200309. 10.1212\/NXI.0000000000200309","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"ref11","article-title":"The nomogram model predicts relapse risk in myelin oligodendrocyte glycoprotein antibody-associated disease: a single-center study","volume":"16","author":"Cheng J","year":"2025","unstructured":"Cheng J, Wang Z, Wang J, et al.. The nomogram model predicts relapse risk in myelin oligodendrocyte glycoprotein antibody-associated disease: a single-center study. Front Immunol. 2025, 16:1527057.","journal-title":"Front Immunol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awx276","article-title":"Clinical presentation and prognosis in MOG-antibody disease: a UK study","volume":"140","author":"Jurynczyk M","year":"2017","unstructured":"Jurynczyk M, Messina S, Woodhall MR, et al.. Clinical presentation and prognosis in MOG-antibody disease: a UK study. Brain. 2017, 140:3128-38. 10.1093\/brain\/awx276","journal-title":"Brain"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-055392","article-title":"Predictors of relapse in MOG antibody associated disease: a cohort study","volume":"11","author":"Huda S","year":"2021","unstructured":"Huda S, Whittam D, Jackson R, et al.. Predictors of relapse in MOG antibody associated disease: a cohort study. BMJ Open. 2021, 11:e055392. 10.1136\/bmjopen-2021-055392","journal-title":"BMJ Open"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000209624","article-title":"Early maintenance treatment initiation and relapse risk mitigation after a first event of MOGAD in adults: the MOGADOR2 study","volume":"103","author":"Deschamps R","year":"2024","unstructured":"Deschamps R, Guillaume J, Ciron J, et al.. Early maintenance treatment initiation and relapse risk mitigation after a first event of MOGAD in adults: the MOGADOR2 study. Neurology. 2024, 103:e209624. 10.1212\/WNL.0000000000209624","journal-title":"Neurology"},{"key":"ref15","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.42780","article-title":"Factors associated with relapse and treatment of myelin oligodendrocyte glycoprotein antibody-associated disease in the United Kingdom","volume":"5","author":"Satukijchai C","year":"2022","unstructured":"Satukijchai C, Mariano R, Messina S, et al.. Factors associated with relapse and treatment of myelin oligodendrocyte glycoprotein antibody-associated disease in the United Kingdom. JAMA Netw Open. 2022, 5:e2142780.","journal-title":"JAMA Netw Open"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2024-333464","article-title":"Predictors of a relapsing course in myelin oligodendrocyte glycoprotein antibody-associated disease","volume":"96","author":"Virupakshaiah A","year":"2024","unstructured":"Virupakshaiah A, Schoeps VA, Race J, et al.. Predictors of a relapsing course in myelin oligodendrocyte glycoprotein antibody-associated disease. J Neurol Neurosurg Psychiatry. 2024, 96:68-75. 10.1136\/jnnp-2024-333464","journal-title":"J Neurol Neurosurg Psychiatry"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/409702-multifocal-presentations-of-myelin-oligodendrocyte-glycoprotein-antibody-associated-disease-mogad-a-case-series-from-a-district-general-hospital-in-south-east-england","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T00:59:56Z","timestamp":1762995596000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/409702-multifocal-presentations-of-myelin-oligodendrocyte-glycoprotein-antibody-associated-disease-mogad-a-case-series-from-a-district-general-hospital-in-south-east-england"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,12]]},"references-count":16,"URL":"https:\/\/doi.org\/10.7759\/cureus.96706","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11,12]]}}}